A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer
1996

Accelerated Chemotherapy for Advanced Ovarian Cancer

Sample size: 22 publication Evidence: moderate

Author Information

Author(s): P Pronzato, G Bertelli, A Viganil, F Vaira

Primary Institution: Ospedale S. Andrea, La Spezia, Italy; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Hypothesis

Can increasing the dose intensity of the PEC chemotherapy regimen improve outcomes in advanced ovarian cancer?

Conclusion

The study shows that an accelerated PEC regimen is feasible and can achieve high dose intensity without severe toxicity.

Supporting Evidence

  • 21 out of 22 patients completed six cycles of treatment.
  • 9 out of 16 evaluable patients achieved a complete clinical response.
  • 90.5% of patients received at least 85% of the planned dose intensity.

Takeaway

Doctors tried giving more chemotherapy to women with advanced ovarian cancer more often, and it worked well without making them very sick.

Methodology

Patients received six cycles of PEC chemotherapy every 14 days with G-CSF support.

Limitations

The study does not conclusively determine the clinical benefits of increased dose intensity.

Participant Demographics

Median age was 51 years, with FIGO stages ranging from IIIA to IV.

Statistical Information

Confidence Interval

95% confidence limits, 77.9% - 100%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication